Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial - Test2 - elhamkhani - TriplyDB

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

http://www.wikidata.org/entity/Q29616259

about

Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting Controlling dengue with vaccines in Thailand Mechanism and significance of cell type-dependent neutralization of flaviviruses Tackling dengue fever: Current status and challenges The global distribution and burden of dengue Global spread of dengue virus types: mapping the 70 year history Discovery of fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue control Structural basis of potent Zika–dengue virus antibody cross-neutralization Rapid and Non-destructive Detection and Identification of Two Strains of Wolbachia in Aedes aegypti by Near-Infrared Spectroscopy Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus Potent Allosteric Dengue Virus NS5 Polymerase Inhibitors: Mechanism of Action and Resistance Profiling Zika virus disease: a current review of the literature Human antibody response to dengue virus: implications for dengue vaccine design The dengue vaccine pipeline: Implications for the future of dengue control Dengue vaccine: a valuable asset for the future The Cellular Bases of Antibody Responses during Dengue Virus Infection Dengue Fever: Causes, Complications, and Vaccine Strategies Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine Systems Biology Approach for Cancer Vaccine Development and Evaluation Introducing a dengue vaccine to Mexico: development of a system for evidence-based public policy recommendations A critical assessment of vector control for dengue prevention Recent Advances in Dengue: Relevance to Puerto Rico Reviewing dengue: still a neglected tropical disease?The yellow fever 17D virus as a platform for new live attenuated vaccines The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response Vaccines for the 21st century Dengue: Moving from Current Standard of Care to State-of-the-Art Treatment Understanding the dengue viruses and progress towards their control Vaccine-mediated immunity against dengue and the potential for long-term protection against disease Latest developments and future directions in dengue vaccines Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes The Spread of Dengue in an Endemic Urban Milieu--The Case of Delhi, India Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial Dengue structure differs at the temperatures of its human and mosquito hosts Cell-targeting antibodies in immunity to Ebola

P2860

Q21562244-BFEB1F0E-0277-42CB-B4C5-E2EDC58193A2 Q21562250-D92120B0-E0A9-4128-9705-CE3E6081BDBA Q23032973-F10B5294-8D00-4B65-AFCA-BED1CD9D2E11 Q24288867-76218603-A802-49E3-97AF-635948AB5FE7 Q24628768-AD090F89-9700-4FFB-ADC9-50AA9AF68027 Q24736362-1D018D8D-3F83-4D1D-A272-CDD2FABBC3A0 Q24736845-74D5CCAF-C02B-4088-8796-B3A9337B3A11 Q24740325-992A6CF0-D838-424D-8347-D74D67FC6CDD Q25202252-67FF2865-CDC0-412B-8F18-31599259B15A Q26247258-8050722E-9092-4E8E-BA26-5101B17C0C7E Q26247399-D3A4E6C2-44F5-453E-A9E6-76C4C6215582 Q26261644-AF154972-976E-4849-8C41-5A4AE0EE507F Q26314609-F4D2B193-EC69-4F17-B264-ED4CED4C58B1 Q26314683-98B2BA25-8A76-44A5-B4B9-210791F7F456 Q26314686-784E1FBF-6951-4079-A6C8-B08BB703A69C Q26700056-910D9B65-993E-4363-B566-6F5BC7F539EB Q26700082-14AF9814-E501-477E-A408-5CBE7DA6DF56 Q26700096-D2259E82-457D-4CC3-B88E-ACF564810EA7 Q26700120-9670E6A0-085B-454D-9600-A347FAAC7851 Q26746185-B477C2B4-33E6-4182-A135-553DB7597B6C Q26782367-57BE9029-A1B6-48B3-B8A4-E3B50780D8C5 Q26782580-B545F8F4-E048-420D-BD5B-36FA29F066A4 Q26823330-3CFA5384-F7EC-4F02-B08F-8A602605F200 Q26824776-0D391087-7240-4073-9D8A-0516A93596A0 Q26825426-629F9956-9161-4C97-B838-9B12153AECC8 Q26825672-8409E5B2-D585-49EE-8833-6B8E70997155 Q26865102-6889E830-3389-47FB-AA60-08EBA00657BD Q26995782-EBC336F7-3D6E-4590-BEFF-7452223CC695 Q27007529-D94B4E51-62D5-4447-AB14-60A61CAF686B Q27010609-4FB80FD1-9B97-4C92-BE98-28323BCEB1AB Q27011587-DB47567A-6DB0-4229-BBC9-361DA216475D Q27014663-61D2DFCC-3C32-4FDF-AA8A-BCC624C4F659 Q27023422-832D9D93-7728-4130-8200-F3136CADB739 Q27303669-E2C6B56D-0FF5-4AB4-B493-EAED7C4D09F5 Q27304342-934E314C-7BE5-4859-9C18-E25FF88A74B1 Q27332223-1F243F9B-7989-4652-AFED-E9CA975E5FA2 Q27334248-F7157B1B-3342-4C62-A278-77CAE9F55E15 Q27468578-B85B2BF5-ECB5-40BA-9793-E73ABB22BEE2 Q27677270-814981DE-AFCC-4B85-B210-0726B31905D0 Q28068972-426616C1-1C20-4D3B-A55A-19C59CA85BA7

P2860

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

http://www.wikidata.org/entity/Q29616259

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Protective efficacy of the rec ...... sed, controlled phase 2b trial

@ast

Protective efficacy of the rec ...... sed, controlled phase 2b trial

@en

type

label

Protective efficacy of the rec ...... sed, controlled phase 2b trial

@ast

Protective efficacy of the rec ...... sed, controlled phase 2b trial

@en

prefLabel

Protective efficacy of the rec ...... sed, controlled phase 2b trial

@ast

Protective efficacy of the rec ...... sed, controlled phase 2b trial

@en

P1433

Q29616259-883EA365-B1E3-4855-9E47-5D04884A1258

P1476

Q29616259-3D564B88-5050-48FC-81E6-BA3EE57D053E

P2093

Q29616259-08E200C3-C355-4F28-9B05-45BFE0D45AAA

Q29616259-0E9502F5-2BDE-4887-9996-C3D8DBC391B0

Q29616259-1CA260ED-C52B-40A8-8E76-A88C3B8E7339

Q29616259-492830D0-D3F4-46C8-B390-6F5DBD4B8A72

Q29616259-5805F0C7-E8E8-434B-9354-5AC39A6697D7

Q29616259-6C5CAAD6-FA3B-4351-887F-83F955A98A6B

Q29616259-78B1309C-FFDD-4BD8-A16B-DA4D6D957E5E

Q29616259-864B31C3-CE2D-438C-942B-B3EC47948A0B

Q29616259-8B5F1CB3-5977-4EB1-BEA6-AD1C4C692F96

Q29616259-A677FB51-8EE4-44C8-9B07-805D47DE3F3B

P304

Q29616259-76A07243-7F8B-4AD3-9118-0313D06CED3B

P31

Q29616259-6728A731-673F-48DD-A47B-B832D431097B

P3181

Q29616259-80F509C3-78D5-4239-B2C5-3D8D3AEC1E51

P356

Q29616259-7FB21310-35A6-4140-A4AC-7CEADD9B2836

P407

Q29616259-8F794098-DFC9-4B91-A2DD-4B49404E6DC8

P433

Q29616259-D4A05CE5-184D-4DB2-BACE-6AA2D50FAD2B

P478

Q29616259-AA011C12-FFC5-47F6-86E5-7C6E50F35C7F

P5008

Q29616259-43DF91F9-16B4-4329-A07E-2783EEDB7CC4

P577

Q29616259-A4146056-2428-41F2-AC1D-06E4FDC49426

P5875

Q29616259-4F2D6CA5-1798-4FDE-8803-AE416582334A

P698

Q29616259-B3E0E4A9-D84D-4E51-945D-14625981FA57

P921

Q29616259-AB32B408-0222-4B97-8A73-9415C9004963

Q29616259-ADFD3F08-662C-4139-95AD-D9B067A4D481

Q29616259-D108B9FB-DF7C-4184-9BB1-E0FDF204EC25

P3181

P356

S0140-6736(12)61428-7

P1433

P1476

Protective efficacy of the rec ...... sed, controlled phase 2b trial

@en

P2093

Bouckenooghe A

http://www.w3.org/2001/XMLSchema#string

Chanthavanich P

http://www.w3.org/2001/XMLSchema#string

Dulyachai W

http://www.w3.org/2001/XMLSchema#string

Jiwariyavej V

http://www.w3.org/2001/XMLSchema#string

Lang J

http://www.w3.org/2001/XMLSchema#string

Limkittikul K

http://www.w3.org/2001/XMLSchema#string

Moureau A

http://www.w3.org/2001/XMLSchema#string

Pengsaa K

http://www.w3.org/2001/XMLSchema#string

Sabchareon A

http://www.w3.org/2001/XMLSchema#string

Saville M

http://www.w3.org/2001/XMLSchema#string

P304

1559-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

357113

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(12)61428-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

9853

http://www.w3.org/2001/XMLSchema#string

P478

380

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2012-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230848750

http://www.w3.org/2001/XMLSchema#string

P698

22975340

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine